四联单片复方制剂对难治性高血压的降压疗效:随机开放标签交叉试验研究方案
本研究为随机开放标签交叉试验,计划纳入40例难治性高血压患者,1:1随机分为两组,分别接受复方利血平氨苯蝶啶片方案(2片奥美沙坦/氨氯地平+1片复方利血平氨苯蝶啶片)与标准方案(2片奥美沙坦/氨氯地平+吲达帕胺2.5 mg+螺内酯20 mg),治疗6周后交换方案再治疗6周,洗脱期4周,主要结局为24小时平均收缩压降幅。
要点
- 难治性高血压定义为至少使用三种降压药后血压仍未控制。
- 研究比较复方利血平氨苯蝶啶片方案与标准四药方案在难治性高血压患者中的疗效与安全性。
- 主要结局为干预6周后两组间24小时平均收缩压降幅的差异。
核心结论
- 本研究旨在评估复方利血平氨苯蝶啶片方案(A+C+0)是否较标准方案(A+C+D+螺内酯)在难治性高血压患者中带来更大的血压降幅。
研究设计与样本
- 随机、开放标签、交叉临床试验,计划招募40例难治性高血压患者,按1:1随机分为2个交叉组。
- 两组分别接受不同联合治疗6周后交换至另一联合治疗6周,洗脱期4周。
- 主要结局为干预6周后两组间24小时平均收缩压降幅的差异。
主要发现
- 原文未报告结果。
关键数值与推荐
- 复方利血平氨苯蝶啶片方案:2片奥美沙坦/氨氯地平(OA)+1片复方利血平氨苯蝶啶片。
- 标准方案:2片OA+吲达帕胺2.5 mg+螺内酯20 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistant hypertension (RH) is defined as uncontrolled blood pressure (BP) despite treatment with at least three or more antihypertensive agents. Compelling evidence has shown that such a population has a greater risk of cardiovascular events as well as mortality. Although mineralocorticoid receptor antagonists (MRAs) have been shown to be an effective fourth-line treatment for RH, a significant proportion of RH patients do not achieve their blood pressure target. Compound reserpine and triamterene tablets, a traditional Chinese quadruple single-pill combination, have been proven to have good antihypertensive effects as well as safety, and are promising effective antihypertensive drugs for treating RH. METHODS: A randomized crossover clinical trial will be conducted to compare the efficacy and safety of compound reserpine and triamterene tablets treatment regimen (two tablets of olmesartan/amlodipine (OA) + one tablet of compound reserpine and triamterene tablets) with those of a standard treatment regimen (two tablets of OA + indapamide 2.5 mg + spironolactone 20 mg) in patients with RH. Forty patients will be recruited and randomly assigned in a 1:1 ratio to 2 crossover groups. The two groups will receive different combination therapies for 6 weeks and will then switch to the other combination therapy for 6 weeks, with a 4-week wash-out. The primary outcome will be the reduction in average 24-h systolic blood pressure after 6 weeks of intervention between the two groups. DISCUSSION: This study aimed to evaluate whether the compound reserpine and triamterene tablets treatment regimen (A + C + 0) results in a greater reduction in blood pressure in RH patients than the standard treatment regimen (A + C + D + spironolactone). TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2400081878. Registered on March 14, 2024 ( http://www.chictr.org.cn ).
引用
- Yao Y, Zhang X, Ye R, et al. The antihypertensive efficacy of a quadruple single-pill combination in patients with resistant hypertension: study protocol for a randomized, open-label, crossover trial. Trials. 2025. PMID: 39833947. doi:10.1186/s13063-025-08719-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。